

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO. 24945-0028US

In re patent application of:
Hans-Peter BUCHSTALLER et al.

Confirmation No.

Applic. No.: 10/564,184

Art Unit: Unassigned

Filed: January 11, 2006

Examiner: Unassigned

For: BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action that would be appropriate to antedate or otherwise remove as a competent reference any document that is determined to be a *prima facie* prior art reference against the claims of the present application.

RELEVANCE STATEMENT

The foregoing documents came to the Applicant's attention during a search of the corresponding international application. A copy of the International Search Report forth the portion of each reference considered relevant by the examiner is attached.

TIMING/FEEs


The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: April 24, 2006

Heller Ehrman LLP
1717 Rhode Island Avenue, NW
Washington, D.C. 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020



Patricia D. Granados
Attorney for Applicant
Reg. No.: 33,683

Customer No. 26633

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Application Number

Complete if Known

10/564.184

Filing Date

January 11, 2006

First Named Inventor

Hans-Peter BUCHSTALLER et al.

Group Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

24945-0028US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	A02	FR 1.517.719	3/22/1968	Inst. Francais Du Petrol		
	A03	EP 0 284 828 A1	10/5/1988	BASF		
	A04	WIPO 98/22103 A1	5/28/1998	Zeneca Limited		
	A05	WIPO 00/18738	4/6/2000	Zeneca Limited		
	A06	EP 1 101 759 A1	5/23/2001	Nippon Soda Co. Ltd.		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/564,184
				Filing Date	January 11, 2006
				First Named Inventor	Hans-Peter BUCHSTALLER et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	24945-0028US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A07	P.A. PETYUNIN et al., Deposited Doc., SPSTL 920 KHP-D82, 1982; XP-002294308; accession no. 101:23395 (DN); RN 90681-10-0; Database Caplus, Chemical Abstracts Service, Columbus, Ohio, US	
	A08	C. CIUGUREANU, Revista De Chimie, Vol. 54, No. 3, 2003, pp. 236-240, Bucharest, Romania, 5 June 2003, XP002294309; Database accession no. 139:292169 (DN); RN 608143-72-2, 608143-73-3, 608143-74-4, 608143-63-1, 608143-64-2, 608143-65-3; Database Caplus, Chemical Abstracts Service, Columbus, OH, US;	
	A09	Database WPI, Section CH, Week 199838k 'Derwent Publications Ltd., London, GB; Class B02, AN 1998-440271, XP002294310; JP 10 182459 A (Otsuka Pharm Co. Ltd); July 7, 1998; abstract, p. 12, scheme	
	A10	PRATIBHA SHARMA et al., "Synthesis of new 2-(substituted benzothiazolylcarbamoyl) benzimidazoles as potential CNS depressants", Indian Journal of Chemistry; November 1999, pp. 1289-1294, Vol. 38B	
	A11	ANTONIO VARNAVAS et al., "Anthranilic acid base CCK antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept", European Journal of Medicinal Chemistry, 2004, pp. 85-97, No. 39	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.